4 not yet recruiting, 4 recruiting, 3 completed. 4 Not applicable, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Major Depressive Disorder (MDD: new trials by email Literature Review of Major Depressive Disorder (MDD trials Research Report on Major Depressive Disorder (MDD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brief Psychoanalytic Therapy Versus Cognitive Behavioral Therapy for Major Depressive Disorder Brief Psychoanalytic Therapy, Cognitive Behavioral Therapy - Major Depressive Disorder (MDD | Not applicable | Not yet recruiting | Istanbul Nisantasi University | 90 | 2026-11-01 | 2026-10-05 |
| Amygdala-Targeted Transcranial Temporal Interference Stimulation for Major Depressive Disorder: A Randomized Sham-Controlled Trial of Clinical Efficacy and Neurobiological Mechanisms Transcranial Temporal Interference Stimulation, Sham Transcranial Temporal Interference Stimulation - Major Depressive Disorder (MDD | Not applicable | Not yet recruiting | Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University | 60 | 2026-10-20 | 2026-09-21 |
| Serotonin Variants & Gut Microbiota in Mental Health SNP Genotyping and Gut Metagenomics - Major Depressive Disorder (MDD, Anxiety Disorder, Generalized | Not yet recruiting | Neurobiologix | 30 | 2026-07-01 | 2026-06-10 | |
| French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments - Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP) | Not applicable | Recruiting | Fondation FondaMental | 3000 | 2026-06-11 | 2026-10-19 |
| Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder Therapeutic intervention - Major Depressive Disorder (MDD | Not yet recruiting | Shanghai Mental Health Center | 130 | 2026-05-30 | 2026-05-22 | |
| EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT Electroconvulsive Therapy - Major Depression Moderate, Major Depression Severe | Recruiting | Istanbul University - Cerrahpasa | 62 | 2026-01-01 | 2026-08-05 | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray - Major Depressive Disorder (MDD | Phase 2 | Completed | Sichuan Purity Pharmaceutical Technology Co., Ltd. | 98 | 2025-05-27 | 2026-09-09 |
| Multimodal Phenotyping in Adolescent Inpatient Depression: An Observational Study data collection and follow-up - Adolescent, Major Depressive Disorder (MDD | Recruiting | Jiangsu Province Nanjing Brain Hospital | 1000 | 2025-03-01 | 2025-11-25 | |
| A Study of ONO-1110 in Patients With Major Depressive Disorder ONO-1110, Placebo - Major Depressive Disorder (MDD | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 103 | 2025-01-16 | 2026-07-08 |
| Psychoeducational Group for Depression PEG-D program, TAU - Major Depressive Disorder (MDD | Not applicable | Recruiting | Ricardo Alberto Moreno, M.D., Ph.D. | 338 | 2024-03-01 | 2024-06-21 |
| Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg - Major Depressive Disorder (MDD | Phase 1 | Completed | Seasons Biotechnology (Taizhou) Co., Ltd. | 30 | 2022-09-19 | 2023-04-13 |
Depressive Disorder, Major (11) · Bipolar Disorder (2) · Depressive Disorder, Treatment-Resistant (2) · Anhedonia (1) · Autism Spectrum Disorder (1) · Depression (1) · Generalized Anxiety Disorder (1) · Panic Disorder (1) · Psychotic Disorders (1) · Schizophrenia (1) · Stress Disorders, Post-Traumatic (1)
Depressive Disorder (11) · Mental Disorders (11) · Mood Disorders (11) · Bipolar and Related Disorders (2) · Anxiety Disorders (1) · Behavior (1) · Behavioral Symptoms (1) · Child Development Disorders, Pervasive (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurodevelopmental Disorders (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Signs and Symptoms (1)
Cognitive Behavioral Therapy (1) · Data Collection (1) · Therapeutics (1)
Fondation FondaMental (1) · Istanbul Nisantasi University (1) · Istanbul University - Cerrahpasa (1) · Jiangsu Province Nanjing Brain Hospital (1) · Neurobiologix (1) · Ono Pharmaceutical Co., Ltd. (1) · Ricardo Alberto Moreno, M.D., Ph.D. (1) · Seasons Biotechnology (Taizhou) Co., Ltd. (1) · Shanghai Mental Health Center (1) · Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University (1) · Sichuan Purity Pharmaceutical Technology Co., Ltd. (1)
China (3) · Turkey (Türkiye) (2) · Brazil (1) · France (1) · India (1) · Japan (1)
Fei Wang (1) · Kanuji Thakor, Ph.D. (1) · Marion Leboyer (1) · Project Leader (1)